clinical trial · NCT04008797
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Endometrial NeoplasmsNeoplasmsCarcinoma, HepatocellularLiver NeoplasmsColorectal NeoplasmsE7386LenvatinibDoxorubicinPaclitaxel
brief summary
The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386 in combination with lenvatinib in endometrial carcinoma (EC) (for EC Dose Optimization Part only).
started
Jul 11, 2019
primary completion
Mar 31, 2027
completion
Mar 31, 2027
last updated
Mar 24, 2026
detailed description
The Dose Escalation and Dose Expansion parts of the study have completed enrollment. The Dose Optimization part of the study is enrolling participants with endometrial carcinoma (EC) only.
official title
An Open-label Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol